etoposide has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 97 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (2.06) | 18.7374 |
| 1990's | 57 (58.76) | 18.2507 |
| 2000's | 23 (23.71) | 29.6817 |
| 2010's | 11 (11.34) | 24.3611 |
| 2020's | 4 (4.12) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Long, L; Wang, J; Xu, Y; Zhang, L | 1 |
| Kannaujiya, VK; Konhäuser, M; Schirmeister, T; Schwickert, K; Steiert, E; Wich, PR | 1 |
| Fan, Z; Lai, Q; Li, S; Liang, A; Luo, H; Wang, F; Wang, G; Wang, J; Xu, J; Xu, Y; Zhang, W; Zhou, J | 1 |
| Bin, T; Chen, S; Chen, X; Cheng, J; Liao, Y; OUYang, J; Zou, W | 1 |
| Chen, XJ; Liu, MY; Wang, WZ; Wu, QQ | 1 |
| Cardarelli, L; Chiaretti, S; Diverio, D; Foà, R; Giona, F; Mancini, F; Miano, M; Moleti, ML; Nanni, M; Palumbo, G; Peragine, N; Santopietro, M; Testi, AM; Zhang, K | 1 |
| Almeida, GM; Guimaraes, JE; Lima, RT; Lopes-Rodrigues, V; Seca, H; Vasconcelos, MH | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Bond, HM; Buffa, P; Consoli, ML; Di Raimondo, F; Manzella, L; Massimino, M; Mesuraca, M; Morrone, G; Pennisi, MS; Romano, C; Sciacca, L; Stagno, F; Stella, S; Tirrò, E; Vigneri, P | 1 |
| Chen, YH; Cheng, L; Jin, XB; Liao, FF; Lin, XH; Liu, MY; Wang, WZ; Wu, QQ; Zhu, JY | 1 |
| Kan, WM; Xiao, LY | 1 |
| Gottlieb, AB; Seidler, AM | 1 |
| Arai, S; Blume, K; Brown, J; Johnston, L; Laport, G; Lowsky, R; Miklos, D; Naik, S; Negrin, R; Shizuru, J; Wong, R | 1 |
| Crowley, LC; Elzinga, BM; McKenna, SL; O'Sullivan, GC | 1 |
| Griaud, F; Pierce, A; Potier, DN; Spooncer, E; Taylor, S; Whetton, AD; Williamson, AJ | 1 |
| Kravchenko, SK; Moiseyeva, TN; Sharkunov, NN; Vinogradova, OY; Zybunova, EE | 1 |
| Axdorph, U; Björkholm, M; Carneskog, J; Grimfors, G; Hansen, J; Linder, O; Ljungman, P; Löfvenberg, E; Malm, C; Simonsson, B; Stenke, L; Turesson, I; Udén, AM; Vilén, L | 1 |
| Adams, R; Albritton, K; Coffin, C; Goldsby, R; Pulsipher, M; Wagner, L | 1 |
| Berger, SJ; Cooper, BW; Donaher, E; Gerson, SL; Gosky, DM; Green, SB; Hoppel, CL; Ingalls, ST; Lazarus, HM; Li, X; Rosenthal, NS | 1 |
| Carroll, M; Dierov, J; Dierova, R | 1 |
| Austin, CA; Ayuso, MJ; Azrak, SS; Cortés, F; López-Lázaro, M; Pastor, N | 1 |
| Bernardini, K; Buratti, T; Lanthaler, AJ; Mitterer, M | 1 |
| Fang, BJ; Song, YP; Wei, XD; Zheng, S | 1 |
| Arruga, F; Bracco, E; Carturan, S; Catalano, R; Chiarenza, A; Cilloni, D; Defilippi, I; Gottardi, E; Messa, F; Morotti, A; Pautasso, M; Rege-Cambrin, G; Rosso, V; Saglio, G; Taulli, R | 1 |
| Balleisen, L; Buss, EC; Emmerich, B; Fischer, T; Fruehauf, S; Hehlmann, R; Ho, AD; Hochhaus, A; Müller, MC; Ottmann, OG; Schuld, P; Topaly, J | 1 |
| Allen, PD; Cotter, FE; Higginbottom, K; Jahnke, U; Newland, AC | 1 |
| Biesma, DH; Grutters, JC; Post, MC; Verzijlbergen, JF | 1 |
| Fioretos, T; Gullberg, U; Lassen, C; Olofsson, T; Richter, J; Svensson, E; Vidovic, K | 1 |
| Alanoğlu, G; Coşkun, HS; Göksu, SS; Sahin, M | 1 |
| Bergamaschi, G; Carella, AM; Cazzola, M; Ferrero, R; Podestá, M; Pollicardo, N; Pungolino, E; Raffo, MR; Rosti, V; Saglio, G | 1 |
| Carella, AM; Ferrero, R; Frassoni, F; Podestá, M; Pollicardo, N; Pungolino, E; Soracco, M | 1 |
| Gastineau, DA; Hoagland, HC; Letendre, L; Noel, P; Solberg, LA; Tefferi, A | 1 |
| Davey, MW; Davey, RA; Hargrave, RM; Kidman, AD | 1 |
| Carella, AM; Frassoni, F; Parodi, C; Podesta, M; Pollicardo, N; Pungolino, E; Rabitti, C; Raffo, MR; Sessarego, M; Vimercati, R | 1 |
| Calvert, L; Claxton, D; Durett, A; Giralt, S; Hamer, J; Kantarjian, H; Khouri, I; Liang, J; Talpaz, M; Tibbits, P | 1 |
| Bedi, A; Fuchs, EJ; Hess, AD; Jones, RJ | 1 |
| Bourdin, S; Harousseau, JL; Le Tortorec, S; Mahe, B; Mahe, JM; Mechinaud-Lacroix, F; Milpied, N; Moreau, P; Rapp, MJ; Wu, DP | 1 |
| Andersson, B; Champlin, R; Deisseroth, AB; Giralt, S; Hester, J; Kantarjian, HM; Khouri, I; Rios, MB; Talpaz, M | 1 |
| Couture, F; Imrie, KR; Keating, A; Sutcliffe, SB; Turner, CC | 1 |
| Amylon, MD; Chao, NJ; Long, GD; Nademanee, AP; Negrin, RS; O'Donnell, MR; Parker, PM; Smith, EP; Snyder, DS; Stein, AS | 1 |
| Cottler-Fox, M; Cowan, K; Dunbar, CE; Goodman, S; Leitman, S; Nienhuis, AW; O'Shaughnessy, J; Quesenberry, P; Sorrentino, BP; Stewart, FM | 1 |
| Allan, WP; Bergoltz, VV; Raymond, J; Ritke, MK; Roberts, D; Yalowich, JC | 1 |
| Björkholm, M; Gruber, A; Liliemark, EK; Liliemark, J; Peterson, C; Pettersson, B | 1 |
| Konaka, Y; Namiuchi, S | 1 |
| Davidson, NE; Desnoyers, S; Kaufmann, SH; Ottaviano, Y; Poirier, GG | 1 |
| Babacan, E; Bökesoy, I; Cavdar, AO; Gözdaşoğlu, S; Pamĭr, A; Sunguroğlu, A; Tanindi, S; Türker, A; Unal, E; Yavuz, G | 1 |
| Beck, WT; Gudkov, AV; Kazarov, AR; Roninson, IB; Suttle, DP; Thimmapaya, R; Zelnick, CR | 1 |
| Carter, C; Hodges, S; Lee, EJ; Reck, K; Schiffer, CA | 1 |
| Bertoglio, J; Bréard, J; Issaad, C; Léglise, MC; Pallardy, M; Roger, R; Turhan, AG | 1 |
| Chen, B; Chen, S; DiGiusto, R; Gearing, D; King, J; Murray, L; Reading, C; Simonetti, D; Tong, J; Van den Berg, D; Wessman, M; Yamasaki, G | 1 |
| Benvenuto, F; Carella, AM; Carlier, P; Chimirri, F; Dejana, A; Ferrara, RA; Florio, G; Frassoni, F; Gatti, AM; Incagliato, M; Lerma, E; Piaggio, G; Pitto, A; Podestà, M; Pollicardo, N; Prencipe, E; Soracco, M; Valbonesi, M; Vassallo, F; Vimercati, R | 1 |
| Carella, AM; Frassoni, F | 2 |
| Amadori, S; Fazi, P; Mandelli, F; Montefusco, E; Petti, MC; Picardi, A; Testi, AM | 1 |
| Atkins, HL; Curtis, JE; Lipton, JH; Messner, HA; Minden, MD | 1 |
| Fujita, S; Hasegawa, A; Hasegawa, H; Hato, T; Ninomiya, H; Takada, K; Yanagisawa, K; Yasukawa, M | 1 |
| Brasseur, N; Gantchev, TG; van Lier, JE | 1 |
| Amill, B; Aventin, A; Azqueta, C; Berlanga, J; Boqué, C; Cancelas, JA; de la Banda, E; Español, JI; Ferrá, C; García, J; Grañena, A; Llucià, M; Muñoz, J; Petit, J; Sarrá, J; Torrico, C | 1 |
| Bewermeier, P; Hossfeld, DK; Kruger, W; Mross, K; Reifke, J; Zander, A | 1 |
| Alimena, G; Amadori, S; Avvisati, G; Capria, S; Celesti, F; Latagliata, R; Mandelli, F; Montefusco, E; Petti, MC | 1 |
| Capria, S; Mandelli, F; Meloni, G; Modena, V; Vignetti, M | 1 |
| Brøndum-Nielsen, K; Johansson, B; Karle, H; Pedersen-Bjergaard, J | 1 |
| Maia, RC; Noronha, H; Rumjanek, VM; Vasconcelos, FC | 1 |
| Amarante-Mendes, GP; Bhalla, K; Green, DR; Huang, Y; Liu, L; Naekyung Kim, C; Perkins, CL | 1 |
| Carriço, MK; Coelho, AM; Klumb, CE; Maia, RC; Noronha, H; Ruimanek, VM; Vasconcelos, FC | 1 |
| Burger, KJ; Heinzinger, M; Lange, W; Rosenstiel, A; Scheid, S; Waller, CF | 1 |
| Akbar, AN; Borthwick, NJ; Bravery, CA; Hart, SM; Hoffbrand, AV; Mehta, AB; Mengubas, K; Ray, N; Riordan, FA; Wickremasinghe, RG | 1 |
| Badri, N; Boogaerts, M; Carella, AM; Dabouz-Harrouche, F; Gautier, L; Gorin, NC; Lennard, A; Link, H; Simonsson, B; Tomas-Martinez, JF | 1 |
| Boqué, C; Grañena, A | 1 |
| Baer, MR; Herzig, GP; Jenis, EH; Mookerjee, BK; Schriber, JR; Shah, M; Wetzler, M | 1 |
| Bartels, H; Bielack, S; Braumann, D; de Wit, M; Dürken, M; Erttmann, R; Fuchs, N; Hegewisch-Becker, S; Kabisch, H; Kröger, N; Krüger, W; Kuse, R; Renges, H; Rüssmann, B; Schuch, G; Stockschläder, M; Wacker-Backhaus, G; Zander, AR | 1 |
| Hayashi, S; Inatomi, Y; Iwama, H; Katagiri, T; Kawakubo, K; Kuriyama, Y; Miyazawa, K; Nehashi, Y; Ohyashiki, K; Shimamoto, T; Shyohji, N; Toyama, K; Uchida, Y; Yaguchi, M | 1 |
| Chiba, S; Hirai, H; Honda, H; Kanda, Y; Yazaki, Y | 1 |
| Amill, B; Aventín, A; Blanco, A; Boqué, C; Brunet, S; González, JR; Grañena, A; Larriba, I; Martín-Henao, GA; Martino, R; Petit, J; Sierra, J; Sureda, A | 1 |
| Menéndez, B; Salar, A; Sierra, J; Sureda, A | 1 |
| Fukumi, S; Horiguchi-Yamada, J; Nagai, M; Nakada, S; Ohno, T; Yamada, H | 1 |
| Esche, H; Opalka, B; Parssanedjad, K; Pützer, BM; Stiewe, T | 1 |
| Carella, AM | 1 |
| Banyai, A; Barta, A; Foldi, J; Gidali, J; Gopcsa, L; Kalasz, L; Pajor, L; Paloczi, K; Regeczy, N | 1 |
| Joel, SP; Lawrence, AJ; Liu, WM | 1 |
| Döhner, H; Gabler, A; Haas, R; Hartmann, F; Hensel, M; Ho, AD; Jung, W; Schlenk, RF; Trümper, L; Weber-Nordt, R | 1 |
| Joel, SP; Liu, WM; Stimson, LA | 1 |
| Armata, J; Balcerska, A; Bogusławska-Jaworska, J; Boruczkowski, D; Bubała, H; Chybicka, A; Cwiklińska, M; Hicke, A; Kaczmarek-Kanold, M; Kałwak, K; Kolecki, P; Kowalczyk, J; Krauze, A; Matysiak, M; Płoszyńska, A; Rokicka-Milewska, R; Sikorska-Fic, B; Sońta-Jakimczyk, D; Staszak-Kowalska, R; Tomaszewska, R; Turkiewicz, D; Wachowiak, J; Wiśniewska-Slusarz, H; Wysocki, M | 1 |
| Constantinou, A; Grdina, D; Huberman, E; Kiguchi, K | 1 |
| Bocheńska, J; Glejzer, O; Jaźwiec, B; Klimczak, A; Kołodziej, J; Pacuszko, T; Sedzimirska, M; Tomaszewska-Toporska, B; Tomeczko, J; Was, A | 1 |
| Andersson, BS; Brunner, LJ; Huan, SD; LeMaistre, CF; Spencer, V; Spinolo, JA; Spitzer, G; Wallerstein, RO; Woo, SY; Yau, JC | 1 |
| Kaito, K; Katayama, T; Kobayashi, M; Masuoka, H; Nishiwaki, K; Ochiai, S; Sakai, O; Shimada, T; Watanabe, R; Yoshida, M | 1 |
| Deisseroth, AB; Dicke, K; Jagannath, S; Kantarjian, HM; LeMaistre, CF; Spinolo, J; Spitzer, G; Talpaz, M; Yau, J | 1 |
| Maca, RD | 1 |
| Dopfer, R; Ehninger, G; Eichel, B; Proksch, B; Schmidt, H; Waidelich, P | 1 |
| Butturini, A; Gale, RP; Reizenstein, P | 1 |
| Brodsky, I; Bulova, S; Conroy, J; Crilley, P; Gryn, J; Kahn, SB; Topolsky, D; Weiss, J | 1 |
| Shionoya, S | 1 |
| Aihara, M; Sasaki, Y; Yoshida, Y | 1 |
| Lee, EJ; Reck, K; Schiffer, CA | 1 |
| Anger, B; Heimpel, H | 1 |
| Dopfer, R; Ehninger, G; Einsele, H; Grosse-Wilde, H; Haen, M; Jaschonek, KG; Pawelec, G; Rutayungwa, ET; Schmidt, H; Schneider, W | 1 |
6 review(s) available for etoposide and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Dermatomyositis induced by drug therapy: a review of case reports.
Topics: Adult; Aged; Antibodies, Antinuclear; Autoimmune Diseases; Cyclophosphamide; Dermatomyositis; Etoposide; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Skin | 2008 |
[Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia].
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Component Removal; Busulfan; Cisplatin; Combined Modality Therapy; Etoposide; Female; Fusion Proteins, bcr-abl; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Ifosfamide; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 1998 |
Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Glomerulosclerosis, Focal Segmental; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Proteinuria | 1998 |
Long-term third chronic phase of chronic myelogenous leukemia maintained by interferon-alpha and methotrexate.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Etoposide; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Methotrexate; Mitoxantrone; Remission Induction; Time; Treatment Outcome | 1999 |
[Allogeneic bone marrow transplantation in myeloid leukemia: chemical conditioning, clinical course and results].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Etoposide; Graft Enhancement, Immunologic; Graft vs Host Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Transplantation, Homologous | 1992 |
Autotransplants in leukemia: current state, future progress.
Topics: Bone Marrow Transplantation; Cyclophosphamide; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Autologous; Twins, Monozygotic | 1991 |
16 trial(s) available for etoposide and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitoxantrone; Prognosis; Remission Induction; Statistics, Nonparametric; Stem Cell Transplantation; Survival Rate | 2002 |
A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Chemical and Drug Induced Liver Injury; DNA Topoisomerases, Type II; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Induction; Enzyme Inhibitors; Etoposide; Female; Gastrointestinal Diseases; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Topoisomerase I Inhibitors; Topotecan | 2003 |
Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cytarabine; Etoposide; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitoxantrone; Piperazines; Pyrimidines; Survival Analysis; Treatment Outcome | 2007 |
Idarubicin-containing regimen and G-CSF are capable of recruiting CD34+/DR- cells with high proliferative potential which sustain Ph-negative polyclonal hematopoiesis.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; HLA-DR Antigens; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged | 1994 |
Idarubicin, intermediate-dose cytarabine, etoposide, and granulocyte-colony-stimulating factor are able to recruit CD34+/HLA-DR- cells during early hematopoietic recovery in accelerated and chronic phases of chronic myeloid leukemia.
Topics: Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; HLA-DR Antigens; Humans; Idarubicin; Interferon-alpha; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Treatment Outcome | 1994 |
Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia.
Topics: Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Humans; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy | 1995 |
High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia.
Topics: Adolescent; Adult; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Transplantation, Autologous; Whole-Body Irradiation | 1994 |
Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Cause of Death; Child; Chromosome Aberrations; Chromosome Disorders; Cyclosporine; Cytogenetics; Drug Therapy, Combination; Etoposide; Female; Graft vs Host Disease; Humans; Immunosuppression Therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Methylprednisolone; Middle Aged; Recurrence; Survival Rate; Whole-Body Irradiation | 1994 |
A phase I trial of carboplatin and etoposide given as continuous infusions to adults with leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1993 |
High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia.
Topics: Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Cisplatin; Combined Modality Therapy; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunologic Factors; Interferon-alpha; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplasm, Residual; Neoplastic Cells, Circulating; Philadelphia Chromosome; Survival Analysis; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 1996 |
A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Carboplatin; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome | 1996 |
Mobilization of peripheral stem cells with intensive chemotherapy (ICE regimen) and G-CSF in chronic myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Separation; Cisplatin; Combined Modality Therapy; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged | 1996 |
Etoposide, intermediate-dose cytarabine and carboplatin (VAC): a combination therapy for the blastic phase of chronic myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Cytarabine; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Remission Induction | 1997 |
Quality of IL-3 and G-CSF-mobilized peripheral blood stem cells in patients with early chronic phase CML.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cells, Cultured; Cisplatin; Combined Modality Therapy; Etoposide; Female; Fusion Proteins, bcr-abl; Gene Rearrangement; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cells; Humans; Ifosfamide; Immunophenotyping; Interferon-alpha; Interleukin-3; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Polymerase Chain Reaction; Recombinant Proteins | 1998 |
Mini-ICE regimen as mobilization therapy for chronic myelogenous leukaemia patients at diagnosis.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Component Removal; Carboplatin; Cytogenetic Analysis; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Leukocytes, Mononuclear; Male; Middle Aged; Neutrophils; Philadelphia Chromosome; Platelet Count; Time Factors; Transplantation, Autologous | 1999 |
Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
75 other study(ies) available for etoposide and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Down-Regulation; Drug Design; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; Humans; Indoles; JNK Mitogen-Activated Protein Kinases; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Dynamics Simulation; Multidrug Resistance-Associated Proteins; Podophyllotoxin; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Signal Transduction; Tubulin | 2018 |
Co-encapsulation of l-asparaginase and etoposide in dextran nanoparticles for synergistic effect in chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Asparaginase; Dextrans; Drug Carriers; Etoposide; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nanoparticles | 2022 |
Checkpoint kinase‑1 inhibition and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia cell line K562 by impairing homologous recombination DNA damage repair.
Topics: 4-Aminopyridine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Checkpoint Kinase 1; Comet Assay; DNA Damage; DNA Repair; Drug Synergism; Etoposide; Homologous Recombination; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrazines; Topoisomerase II Inhibitors | 2020 |
Secondary chronic myeloid leukemia following acute myeloid leukemia treated with autologous hematopoietic stem cell transplantation: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Pyrimidines; Remission Induction; Transplantation, Autologous | 2020 |
[Effect of Etoposide on Elimination of Chronic Myeloid Leukemia Stem Cells by Imatinib in Vivo].
Topics: Animals; Drug Resistance, Neoplasm; Etoposide; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Stem Cells | 2021 |
Atypical Chronic Myeloid Leukemia in a Patient with Aplastic Anemia.
Topics: Adolescent; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Etoposide; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methylprednisolone; Prednisolone; Pyridazines | 2019 |
Targeting miR-21 induces autophagy and chemosensitivity of leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; Etoposide; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs | 2013 |
Fifteenth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Cyclophosphamide; Dasatinib; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Staging; Piperazines; Platelet Transfusion; Prednisone; Primary Prevention; Procarbazine; Pyrimidines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Survival Analysis; Thiazoles; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome; Vincristine; Vindesine | 2013 |
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.
Topics: Benzamides; Catalysis; Cell Line, Tumor; Cell Proliferation; Etoposide; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon Regulatory Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Protein Binding; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Signal Transduction; Transcriptional Activation; Tumor Stem Cell Assay | 2014 |
Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
Topics: Antigens, CD34; Apoptosis; Cell Line, Tumor; Cell Survival; Etoposide; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Signal Transduction; Topoisomerase II Inhibitors; Tumor Stem Cell Assay | 2017 |
Cyclic AMP (cAMP) confers drug resistance against DNA damaging agents via PKAIA in CML cells.
Topics: Bucladesine; Cell Death; Cisplatin; Colforsin; Cyclic AMP; Cyclic AMP-Dependent Protein Kinase Type I; DNA Damage; Drug Resistance, Neoplasm; Etoposide; Humans; Intracellular Space; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Signal Transduction | 2017 |
Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY.
Topics: Adult; Busulfan; Cyclophosphamide; Cytomegalovirus; Etoposide; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Transplantation Conditioning; Treatment Outcome; Virus Activation | 2011 |
Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment.
Topics: Animals; Autophagy; Benzamides; Cell Line, Tumor; DNA Damage; Doxorubicin; Etoposide; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Targeted Therapy; Piperazines; Pyrimidines; RNA, Small Interfering; Transfection | 2011 |
BCR/ABL modulates protein phosphorylation associated with the etoposide-induced DNA damage response.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; DNA Damage; Etoposide; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Nuclear Proteins; Phosphorylation; Protein-Tyrosine Kinases | 2012 |
[Successful treatment for Hodgkin's lymphoma in a female patient with Ph+ chronic myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prednisone; Procarbazine; Pyrimidines; Remission Induction; Treatment Outcome; Vincristine | 2012 |
Unexpected pleural effusions in 3 pediatric patients treated with STI-571.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Camptothecin; Child; Combined Modality Therapy; Edema; Enzyme Inhibitors; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Lung Neoplasms; Male; Neoplasm Proteins; Neuroectodermal Tumors, Primitive; Piperazines; Pleural Effusion; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Sarcoma, Ewing; Testis; Topotecan | 2002 |
BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint.
Topics: Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Nucleus; Cells, Cultured; Cytoplasm; DNA Damage; DNA Repair; DNA Topoisomerases, Type II; Enzyme Inhibitors; Etoposide; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Serine-Threonine Kinases; Protein Transport; S Phase; Signal Transduction | 2004 |
Digitoxin, at concentrations commonly found in the plasma of cardiac patients, antagonizes etoposide and idarubicin activity in K562 leukemia cells.
Topics: Amsacrine; Antineoplastic Agents; Digitoxin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Etoposide; Humans; Idarubicin; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitoxantrone; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2006 |
Monolateral renal infarction and erythromelalgia in a case of chronic myelogenous leukemia.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Erythromelalgia; Etoposide; Female; Humans; Hydroxyurea; Imatinib Mesylate; Infarction; Interferon-alpha; Kidney; Kidney Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Radiography | 2006 |
[Study on the mechanisms of imatinib-resistance of cancer stem-like cells in K562/Vp16 cell line].
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Drug Resistance, Neoplasm; Etoposide; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Pyrimidines | 2005 |
NF-kB inhibition as a strategy to enhance etoposide-induced apoptosis in K562 cell line.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Blast Crisis; Cell Survival; Down-Regulation; Drug Synergism; Etoposide; Gene Expression Regulation, Leukemic; Humans; I-kappa B Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; NF-kappa B | 2006 |
Cell death in leukemia: passenger protein regulation by topoisomerase inhibitors.
Topics: Antineoplastic Agents, Phytogenic; Aurora Kinase B; Aurora Kinases; CDC2 Protein Kinase; Cell Death; Chromosomes, Human; Enzyme Inhibitors; Etoposide; G2 Phase; Histones; Humans; Inhibitor of Apoptosis Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microtubule-Associated Proteins; Mitosis; Neoplasm Proteins; Protein Serine-Threonine Kinases; Survivin; Topoisomerase II Inhibitors | 2007 |
PET scintigraphy of etoposide-induced pulmonary toxicity.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Etoposide; Fluorodeoxyglucose F18; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Diseases; Male; Positron-Emission Tomography; Radiopharmaceuticals; Rare Diseases | 2007 |
Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells.
Topics: Apoptosis; Benzamides; Cell Line, Tumor; Cells, Cultured; Chromones; Drug Resistance, Neoplasm; Etoposide; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genes, Wilms Tumor; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Inositol; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Morpholines; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Recombinant Fusion Proteins; RNA, Neoplasm; Signal Transduction; Transduction, Genetic; WT1 Proteins | 2007 |
Bleomycin, etoposide and cisplatin (BEP) combination with concurrent imatinib mesylate (GLEEVEC) in chronic myeloid leukemia (CML) patient with mesenchymal tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Cisplatin; Etoposide; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mesenchymoma; Piperazines; Pyrimidines | 2008 |
Development of drug resistance is reduced with idarubicin relative to other anthracyclines.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Survival; Drug Interactions; Drug Resistance, Multiple; Etoposide; Flow Cytometry; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Tumor Cells, Cultured; Verapamil | 1995 |
Collection of 'normal' blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Blood Transfusion, Autologous; Cell Separation; Combined Modality Therapy; Cytarabine; Etoposide; Female; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Idarubicin; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Polymerase Chain Reaction; Recombinant Proteins; Remission Induction; RNA, Messenger; RNA, Neoplasm; Time Factors; Treatment Outcome | 1993 |
Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autolog
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Daunorubicin; Diploidy; Etoposide; Female; Genetic Markers; Hematopoietic Stem Cells; Humans; Idarubicin; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Philadelphia Chromosome; Remission Induction; Survival Rate; Vidarabine; Whole-Body Irradiation | 1995 |
Cytotoxic T cells overcome BCR-ABL-mediated resistance to apoptosis.
Topics: Animals; Apoptosis; Cell Line; Cell Nucleus; Cell Survival; Cells, Cultured; Cytotoxicity, Immunologic; DNA Damage; Etoposide; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred C57BL; Spleen; T-Lymphocytes, Cytotoxic; Transfection | 1995 |
Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Recurrence; Time Factors; Transplantation, Homologous; Whole-Body Irradiation | 1994 |
Peripheral neuropathy following high-dose etoposide and autologous bone marrow transplantation.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Combined Modality Therapy; Etoposide; Female; Hodgkin Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Male; Peripheral Nervous System Diseases; Transplantation, Autologous | 1994 |
Amendment to clinical research projects. Genetic marking with retroviral vectors to study the feasibility of stem cell gene transfer and the biology of hematopoietic reconstitution after autologous transplantation in multiple myeloma, chronic myelogenous
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Breast Neoplasms; Cisplatin; Clinical Protocols; Combined Modality Therapy; Cyclophosphamide; Etoposide; Feasibility Studies; Genetic Therapy; Genetic Vectors; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melphalan; Multiple Myeloma; Neoplasm Metastasis; Retroviridae; Transfection; Transplantation, Autologous; Whole-Body Irradiation | 1993 |
Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.
Topics: Antineoplastic Agents; Cell Nucleus; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Resistance; Etoposide; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; RNA, Neoplasm; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1994 |
In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Blood Proteins; Cytarabine; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Protein Binding; Serum Albumin; Topoisomerase II Inhibitors | 1993 |
[Extramedullary blast crisis of mixed precursor T lymphoblastic and myeloblastic features in a patient with chronic myelogenous leukemia successfully treated with low-dose oral etoposide].
Topics: Administration, Oral; Blast Crisis; Bone Marrow; Etoposide; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, T-Cell; Lymph Nodes; Male; Mediastinal Neoplasms; Middle Aged; Remission Induction; T-Lymphocytes | 1993 |
Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Etoposide; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Molecular Weight; NAD; Peptide Fragments; Poly(ADP-ribose) Polymerases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protease Inhibitors | 1993 |
Orbito-ocular granulocytic sarcoma (OOGS) and acute myeloblastic leukemia (AML) with duplication of Philadelphia chromosome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Eye Neoplasms; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Methotrexate; Multigene Family; Neoplasms, Multiple Primary; Orbital Neoplasms; Philadelphia Chromosome; Thioguanine | 1993 |
Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA.
Topics: Antineoplastic Agents; Base Sequence; Cloning, Molecular; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Resistance; Etoposide; Gene Library; Genes, Suppressor; HeLa Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Sequence Data; Oligodeoxyribonucleotides; Plasmids; Polymerase Chain Reaction; Retroviridae; RNA, Antisense; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1993 |
BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells.
Topics: Apoptosis; Camptothecin; Cycloheximide; Cytotoxicity, Immunologic; Dactinomycin; DNA Damage; DNA, Neoplasm; Etoposide; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Hydrogen Peroxide; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Leukemia, Megakaryoblastic, Acute; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Puromycin; Recombinant Fusion Proteins; Transfection; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1996 |
Leukemic burden in subpopulations of CD34+ cells isolated from the mobilized peripheral blood of alpha-interferon-resistant or -intolerant patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Animals; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Blood Cell Count; Bone Transplantation; Cisplatin; Combined Modality Therapy; Drug Resistance; Etoposide; Fetal Tissue Transplantation; Flow Cytometry; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; Immunologic Factors; Immunomagnetic Separation; In Situ Hybridization, Fluorescence; Interferon-alpha; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Mice; Mice, SCID; Middle Aged; Neoplasm Transplantation; Neoplastic Cells, Circulating; Philadelphia Chromosome; Radiation Chimera; Specific Pathogen-Free Organisms; Transplantation, Heterologous | 1996 |
Collection, analysis and transplantation of Ph-negative blood precursor cells in chronic myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Recurrence; Remission Induction; Transplantation, Autologous | 1996 |
Intensive remission induction therapy for chronic myeloid leukemia in blast phase with a goal of post-remission bone marrow transplant--a pilot study.
Topics: Adolescent; Adult; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Etoposide; Female; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Pilot Projects; Remission Induction; Survival Rate; Vincristine | 1996 |
ICE, mini-ICE or high-dose hydroxyurea to mobilize Philadelphia (Ph1)-negative PBPC in chronic myelogenous leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Ifosfamide; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1996 |
[Successful treatment of combined interferon-alpha and hydroxycarbamide for chronic myelogenous leukemia following therapy for malignant lymphoma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; Female; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Follicular; Middle Aged; Neoplasms, Second Primary | 1996 |
Combination toxicity of etoposide (VP-16) and photosensitisation with a water-soluble aluminium phthalocyanine in K562 human leukaemic cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Division; Combined Modality Therapy; DNA, Neoplasm; Drug Interactions; Etoposide; Humans; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nucleosomes; Organometallic Compounds; Photochemotherapy; Photosensitizing Agents; Tumor Cells, Cultured | 1996 |
The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Evaluation Studies as Topic; Humans; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute | 1996 |
Blast crisis of chronic myelogenous leukemia in long-lasting systemic lupus erythematosus: regression of both diseases after autologous bone marrow transplantation.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Blast Crisis; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Idarubicin; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lupus Erythematosus, Systemic; Methotrexate; Prednisone; Remission Induction; Transplantation, Autologous; Vincristine | 1997 |
Chemotherapy-related - late occurring - Philadelphia chromosome in AML, ALL and CML. Similar events related to treatment with DNA topoisomerase II inhibitors?
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Topoisomerase II Inhibitors | 1997 |
Interaction of cyclosporin A and etoposide. Clinical and in vitro assessment in blast phase of chronic myeloid leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cyclosporine; Drug Interactions; Etoposide; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male | 1997 |
Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspases; Cysteine Endopeptidases; Cytarabine; Cytochrome c Group; Enzyme Activation; Etoposide; Fusion Proteins, bcr-abl; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Membrane Potentials; Mitochondria; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Sphingolipids; Transfection; Tumor Cells, Cultured | 1998 |
Clinical approach to circumvention of multidrug resistance in refractory leukemic patients: association of cyclosporin A with etoposide.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Child; Cyclosporine; Drug Resistance, Multiple; Etoposide; Female; Growth Inhibitors; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured | 1997 |
Herbimycin A accelerates the induction of apoptosis following etoposide treatment or gamma-irradiation of bcr/abl-positive leukaemia cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Benzoquinones; Etoposide; Fusion Proteins, bcr-abl; Gamma Rays; HL-60 Cells; Humans; Lactams, Macrocyclic; Leukemia, Erythroblastic, Acute; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Proto-Oncogene Proteins c-bcl-2; Quinones; Rifabutin; Tumor Cells, Cultured | 1998 |
Mobilization of Philadelphia-negative peripheral blood progenitor cells with chemotherapy and rhuG-CSF in chronic myelogenous leukaemia patients with a poor response to interferon-alpha.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Interferon-alpha; Lenograstim; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Recombinant Proteins; Treatment Outcome | 1998 |
Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bone Marrow Transplantation; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Recurrence; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Whole-Body Irradiation | 1998 |
[Induction of Ph-negative normal clone and long-term survival by combined treatment with G-CSF plus middle dose cytosine arabinoside for patients with chronic myeloid leukemia in blastic transformation].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Clone Cells; Cytarabine; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Survivors | 1998 |
Mini-ICE regimen allows mobilization of peripheral blood progenitor cells in a patient with chronic myelogenous leukemia failing the ICE protocol.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Ifosfamide; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male | 2000 |
Differential responses of Bcl-2 family genes to etoposide in chronic myeloid leukemia K562 cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Caspase 3; Caspases; DNA Damage; DNA Primers; DNA, Neoplasm; Dose-Response Relationship, Drug; Down-Regulation; Etoposide; Gene Expression Regulation; Genes, bcl-2; Humans; Immunoblotting; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microscopy, Fluorescence; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2000 |
E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents.
Topics: Adenovirus E1A Proteins; Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; Caspase 3; Caspases; CDC2 Protein Kinase; Cell Cycle; Cell Division; Daunorubicin; DNA Damage; Dose-Response Relationship, Drug; Etoposide; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; K562 Cells; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Luciferases; Microscopy, Phase-Contrast; Nucleic Acid Synthesis Inhibitors; Peptides; Plasmids; Poly(ADP-ribose) Polymerases; Transfection; Tumor Cells, Cultured | 2000 |
Mini-ice protocol is better than high-dose hydroxyurea to mobilize Ph-negative cells in earlier phases of chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Hydroxyurea; Ifosfamide; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Treatment Outcome | 2001 |
Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia with different clinical stages.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Purging; Caspase 14; Caspases; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Recombinant Proteins; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2001 |
The importance of drug scheduling and recovery phases in determining drug activity. Improving etoposide efficacy in BCR-ABL-positive CML cells.
Topics: CDC2 Protein Kinase; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Flow Cytometry; Fusion Proteins, bcr-abl; G2 Phase; Humans; Immunoblotting; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Tumor Cells, Cultured | 2002 |
The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents.
Topics: Antineoplastic Agents; Benzamides; Cell Death; Cytarabine; Enzyme Inhibitors; Etoposide; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunoblotting; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tumor Cells, Cultured | 2002 |
[Results of treatment of children with chronic myelogenous leukaemia (CML) obtained by the Polish Paediatric Leukaemia/Lymphoma Study Group].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Humans; Hydroxyurea; Infant; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mercaptopurine; Poland; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2000 |
The effect of topoisomerase inhibitors on the expression of differentiation markers and cell cycle progression in human K-562 leukemia cells.
Topics: Amsacrine; Aphidicolin; Cell Cycle; Cell Differentiation; Cycloheximide; Deoxyadenosines; Dose-Response Relationship, Drug; Etoposide; G2 Phase; Hemoglobins; Humans; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melanins; Mitosis; Novobiocin; Teniposide; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1992 |
Allogeneic bone marrow transplantation for hematological malignancies following etoposide, cyclophosphamide, and fractionated total body irradiation.
Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Female; Humans; Injections, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Transplantation, Homologous; Whole-Body Irradiation | 1992 |
[Successful low-dose etoposide therapy for a case of myelofibrosis with chronic myelogenous leukemia megakaryocytic predominance type].
Topics: Adult; Blast Crisis; Bone Marrow; Cell Count; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Megakaryocytes; Primary Myelofibrosis | 1992 |
Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Granulocytes; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Interferon Type I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Macrophages; Male; Metaphase; Middle Aged; Philadelphia Chromosome; Remission Induction; Time Factors | 1991 |
Enhancement of etoposide and methotrexate sensitivity by indomethacin in vitro.
Topics: Animals; Bleomycin; Drug Synergism; Etoposide; Humans; Indomethacin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipoxygenase Inhibitors; Lung Neoplasms; Lymphoma; Methotrexate; Neoplasms, Experimental; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostaglandins; Protein Kinase Inhibitors; Tumor Cells, Cultured | 1991 |
Unaltered pharmacokinetics after the administration of high-dose etoposide without prior dilution.
Topics: Acute Disease; Adolescent; Adult; Biological Availability; Bone Marrow Transplantation; Chromatography, High Pressure Liquid; Combined Modality Therapy; Etoposide; Humans; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy Dosage | 1991 |
High-dose cytosine arabinoside and etoposide in the treatment of relapsed or refractory adult leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Survival Rate | 1991 |
Etoposide inhibition of methylaminoisobutyric acid transport and its recovery in K562 cells.
Topics: Aminoisobutyric Acids; Biological Transport; Cell Division; Cycloheximide; Depression, Chemical; Etoposide; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Sodium; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1991 |
[Successful therapy of Ph1 positive chronic myelocytic leukemia with oral form of etoposide].
Topics: Administration, Oral; Adult; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1990 |
Continuous infusion diaziquone and etoposide: a phase I study in adult patients with acute leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Blast Crisis; Bone Marrow; Drug Evaluation; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1990 |
Daunomycin, cytosin-arabinoside and VP-16 (DAV) for myeloid blast crisis of CML.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Thioguanine | 1989 |
[Transplantation of bone marrow from unrelated donors in chronic myeloid leukemia].
Topics: Bone Marrow Transplantation; Chronic Disease; Cyclophosphamide; Cyclosporins; Drug Therapy, Combination; Etoposide; Graft vs Host Reaction; HLA Antigens; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Tissue Donors; Whole-Body Irradiation | 1989 |